Free speech in prescription drug marketing will get a fresh look on Thursday when a federal appeals court in San Francisco considers whether a biotech executive committed fraud in touting a lung-disease drug.
Courts to weigh free speech in drug marketing cases
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.